Open Beta
TREN
MetriLume
TREN

US marketsTARS

SEC-sourced researchBeta

TARS

Tarsus Pharmaceuticals, Inc.

Company comparison ↗

Data passport

CIK
0001819790
Exchange
Nasdaq
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Sep 17, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 17,447,000.0000 USD; December 2024: 182,953,000.0000 USD; December 2025: 451,360,000.0000 USD451.4M USD0 USD0December 2023December 2024December 2025
TARS · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202317,447,000.0000Feb 23, 2026
December 2024182,953,000.0000Feb 23, 2026
December 2025451,360,000.0000Feb 23, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025451,360,000.0000-66,418,000.0000-12,451,000.0000562,158,000.0000218,732,000.0000Feb 23, 2026
December 2024182,953,000.0000-115,554,000.0000-83,027,000.0000376,991,000.0000152,457,000.0000Feb 23, 2026
December 202317,447,000.0000-135,893,000.0000-117,493,000.0000——Feb 23, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$451.36MDecember 2025Feb 23, 202610-K
Previous period revenueRevenues$182.95MDecember 2024Feb 23, 202610-K
Net incomeNetIncomeLoss-$66.42MDecember 2025Feb 23, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$12.45MDecember 2025Feb 23, 202610-K
Total assetsAssets$562.16MDecember 2025Feb 23, 202610-K
Total liabilitiesLiabilities$218.73MDecember 2025Feb 23, 202610-K

New filings

Explore methodology ↗